(Rac)-Apremilast  (Synonyms: (Rac)-CC-10004)

(Rac)-Apremilast ((Rac)-CC-10004) is the racemic mixture of Apremilast. (Rac)-Apremilast has anti-inflammatory properties and can be used for research on inflammatory diseases, such as psoriasis^[1][2].

460.50

C₂₂H₂₄N₂O₇S

253168-86-4

Solid

Light yellow to yellow

CC(NC1=CC=CC(C(N2C(C3=CC=C(OC)C(OCC)=C3)CS(=O)(C)=O)=O)=C1C2=O)=O

Room temperature in continental US; may vary elsewhere.

• [1]. Armstrong AW, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023 Jan;88(1):29-39.  [Content Brief]

  [2]. Man H W, et al. Discovery of (S)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1, 3-dioxo-2, 3-dihydro-1 H-isoindol-4-yl} acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-α inhibitor[J]. Journal of medicinal chemistry, 2009, 52(6): 1522-1524.